PTK2 and acute lymphoblastic leukemia: Since increasing evidence has demonstrated the role of various tyrosine kinases such as IGF1R [35], TYK2 [36], or FAK kinases [37] in T-ALL pathogenesis, we identified a kinase inhibitor to synergize with SET antagonism and enhance the potency of OP449.